Insight journal, Insight journal - Company

Isis Pharmaceuticals: Partnering activity 2009-2014

Posted on 15 September 2014

Tags: , ,

Isis Pharmaceuticals, a leader in antisense drug discovery, has emerged as a top 50 big biotech company with its business strategy. The big biotech company, headquartered in the United States, works on the early stage development of drugs and finds partners to out-license them to.

The company’s partnering activity is reviewed in the article. The following figure shows the frequency of Isis Pharmaceutical's partnering deal announcements since 2009.

Figure 1: Isis Pharmaceuticals partnering deals 2009-2014

Figure 1: Isis Pharmaceuticals partnering deals 2009-2014

Figure 1: Isis Pharmaceuticals partnering deals 2009-2014

 

Source: Current Agreements, 2014

The figure above illustrates the high partnering activity conducted by Isis Pharmaceuticals. The company’s core business strategy is to broaden its product portfolio by partnering which makes it a sought after partner by big pharma.

The company has a number of products in early stage of development and has partnered them successfully with companies like Genzyme, GSK, Biogen Idec, Roche, Regulus in the areas of rare diseases, cardiovascular, metabolic, cancer and inflammation.

The following table provides an overview of the partnering deals announced by Isis Pharmaceuticals based on therapy area disclosed. Our report provides a more detailed insight into the precise therapeutic target of each deal.

See: Report: Partnering Agreements with Isis Pharmaceuticals 2009-2014

Figure 2: Isis Pharmaceuticals partnering deals by therapy area 2009-2014

Figure 2: Isis Pharmaceuticals partnering deals by therapy area 2009-2014

Figure 2: Isis Pharmaceuticals partnering deals by therapy area 2009-2014

Source: Current Agreements, 2014

Further analysis of these deals shows that Isis Pharmaceuticals has a preference for licensing, collaborative R&D and option deals, similar to many other top pharmaceutical or big biotech companies. Such partnering deals provide the right for Isis Pharmaceuticals to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.

The following table provides an overview of the partnering deals announced by Isis Pharmaceuticals based on deal type disclosed.

Figure 3: Isis Pharmaceuticals partnering deals by deal type 2009-2014

Figure 3: Isis Pharmaceuticals partnering deals by deal type 2009-2014

Figure 3: Isis Pharmaceuticals partnering deals by deal type 2009-2014

Source: Current Agreements, 2014

When looking at stage of development of partnering at deal signing, the most popular stages are early stage development. The company’s strategy is to conduct early stage drug development and out license drugs to maximize the value of the drugs with companies with late stage development expertise.

The following table provides an overview of the partnering deals announced by Isis Pharmaceuticals based on stage of development at signature.

Figure 4: Isis Pharmaceuticals partnering by stage of development 2009-2014

Figure 4: Isis Pharmaceuticals partnering by stage of development 2009-2014

Figure 4: Isis Pharmaceuticals partnering by stage of development 2009-2014

Source: Current Agreements, 2014

Isis Pharmaceuticals has signed over 30 partnering, collaborative R&D and licensing deals since 2009. Partnering with big pharma companies like GSK, AstraZeneca and Biogen Idec, the company has signed very high value deals for antisense therapeutics. The following provides a summary of the top deals by headline value.

Figure 5: Top Isis Pharmaceuticals partnering deals by headline value 2009-2014

Figure 5: Top Isis Pharmaceuticals partnering deals by headline value 2009-2014

Source: Current Agreements, 2014

It is very clear that the company owes its growth and range of products to its partnering strategy.

Our report provides more detailed insight into the details of each deal.

See: Report: Partnering Agreements with Isis Pharmaceuticals 2009-2014

Isis Pharmaceuticals partnering at Current Agreements

View all partnering deals for Isis Pharmaceuticals: 2014 | 2013 | 2012 | 2011 | 2010 | 2009 

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Report: Partnering Agreements with Isis Pharmaceuticals 2009-2014

More 

Summary profile data for Isis Pharmaceuticals

Partnering interests for Isis Pharmaceuticals

No M&A activity for Isis Pharmaceuticals

Available reports from Current Partnering

Report: Partnering Agreements with Isis Pharmaceuticals 2009-2014

Report: Partnering Deals and Alliances with Big Biotech

Available resources for deal coverage for Isis Pharmaceuticals       

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Isis Pharmaceuticals company profile, recent partnering, M&A and financing news and articles

Related

Report: Practical Guide to Finding Partners

View: CP Insight’s Partnering Scorecard – view top life science partnering deals by value

View: CP Insight’s M&A Scorecard – view top life science M&A deals by value

View: CP Insight Deal Monitor’s Deal Metrics – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: CP Insight’s Top  50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: CP Insights’s Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply